Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes: the TA trial
- Conditions
- Coronary artery diseaseHeart DiseasesSurgery - Surgical techniques
- Registration Number
- ACTRN12623000864628
- Lead Sponsor
- Melbourne Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Participating institutions within Australia. Primary isolated adult CABG patients with multivessel coronary disease requiring at least two grafts.
Previous cardiac surgery involving sternotomy
Emergency operation
Preoperative myocardial infarction within 48 hours
Planned hybrid revascularisation
Preoperative severe end-organ dysfunction (Troponin I > 20,000 within five days of surgery
Ejection fraction less than or equal to 20%
Current inotrope or vasoconstrictor requirement
Respiratory pressure support or intubation
Acute renal failure or renal replacement therapy <4 weeks
Cerebrovascular event of any kind <6 weeks before surgery
Cancer or any comorbidity that reduces life expectancy to less than five years
Planned concomitant procedure (including coronary endarterectomy and excepting for left atrial appendage occlusion or epicardial pacemaker lead placement)
Inability to participate in postoperative follow-up or CTCA including allergy to radiology contrast medium will be excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method